Impact Biomedical (IBO) Receivables - Net (2024 - 2025)
Impact Biomedical's (IBO) quarterly Receivables - Net came in at $5000.0 in Q4 2025, down 97.51% on a YoY basis from $201000.0 in Q4 2024, and down 97.49% quarter-over-quarter from $199000.0 in Q3 2025.
Powered by 
Analysis
Impact Biomedical (IBO) Receivables - Net (2024 - 2025) Analysis & Trends
Impact Biomedical (IBO) has reported Receivables - Net for 2 consecutive years, with $5000.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Receivables - Net fell 97.51% year-over-year to $5000.0; the trailing twelve-month figure through Dec 2025 stood at $5000.0 (down 97.51% YoY), and the FY2025 full-year result was $5000.0, down 97.51% from the prior year.
- Receivables - Net retreated to $5000.0 in Q4 2025 per IBO's latest filing, from $199000.0 in the prior quarter.
- Across five years, Receivables - Net topped out at $201000.0 in Q4 2024 and bottomed at $5000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Impact Biomedical | 49.63 Mn | 49.62 Mn | 2,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 5,000.00 |
| Sep 30, 2025 | 199,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Dec 31, 2024 | 201,000.00 |
| Jun 30, 2024 | 128,000.00 |
| Mar 31, 2024 | 128,000.00 |